MedTrace Logo

Combination of Biologic and Anti-obesity Therapies in Psoriatic Arthritis

NCT07443956 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2026-05-04

No results posted yet for this study

Summary

This is a trial to find out how weight loss (achieved by the use of tirzepatide) or ixekizumab treatment affects the characteristics of skin, joint and fat tissues in patients with Psoriatic Arthritis, Psoriasis and obesity/overweight BMI \>=27.

Participants will be allocated either Tirzepatide, Ixekizumab or both. Samples of joint tissue, fat and skin will be taken at the start of the study and week 12. Blood and urine samples will also be taken.

The primary objective will be to assess the changes seen in the joint, fat and skin tissue samples 12 weeks after starting the medications (additional analysis will be done on the optional 36 week samples).

Secondary objectives will be

* To assess the changes seen in blood 4, 12, 36 and 52 weeks after starting the medication.
* To compare the changes seen in tissue and blood between Ixekizumab and Tirzepatide/Weight loss.
* To see how the changes seen in the tissue relate to weight loss.

Conditions

  • Psoriatic Arthritis (PsA)
  • Obesity & Overweight

Interventions

DRUG

Ixekizumab

anti-IL17A monoclonal antibody

DRUG

Tirzepatide

GLP-1 and GIP agonist

Sponsors & Collaborators

  • University of Glasgow

    collaborator OTHER

  • Eli Lilly and Company

    collaborator INDUSTRY

  • NHS Greater Glasgow and Clyde

    lead OTHER

Principal Investigators

  • Carl Goodyear, PhD, · University of Glasgow

  • Naveed Sattar, MBChB, PhD, · University of Glasgow

  • Lyn Ferguson, MBChB, PhD, · University of Glasgow

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-09
Primary Completion
2028-02-29
Completion
2030-05-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07443956 on ClinicalTrials.gov